Sort
21,281 grants matching “influenza”
Development of Membrane Anchored Cytokines as Novel Vaccine Adjuvants for the Elderly
$1,948,234Christopher Pack · Metaclipse Therapeutics Corporation · N44 · FY2019 · AI
Hazardous Waste Worker Training Program (HWWTP)
$1,943,056Frank Stephen Cyphers · International Chemical Workers Union · U45 · FY2014 · ES
Adjuvant Discovery for Vaccines against Influenza Virus
$1,942,519Ofer Levy · Boston Children'S Hospital · N01 · FY2015 · AI
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: UNIVERSAL INFLUENZA RESEARCH
$1,940,444Richard Webby · St. Jude Children'S Research Hospital · N01 · FY2022 · AI
Host-pathogen competition in IFN mediated antiviral defense
$1,939,033Jae U Jung · University Of Southern California · U19 · FY2010 · AI
Collectins and Innate Defense against Inhaled Pathogens
$1,938,284Barbara A Seaton · Boston University Medical Campus · P01 · FY2010 · AI
Host-pathogen competition in IFN mediated antiviral defense
$1,936,252Jae U Jung · University Of Southern California · U19 · FY2012 · AI
Surveillance for Vaccine Preventable Disease in Children
$1,936,000Julie Anne Boom · Baylor College Of Medicine · U01 · FY2022 · IP
IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,936,000Rangaraj Selvarangan · Children'S Mercy Hosp (Kansas City, Mo) · U01 · FY2022 · IP
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness
$1,936,000Geoffrey Alan Weinberg · University Of Rochester · U01 · FY2022 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,936,000Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2022 · IP
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,935,998Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2022 · IP
In Vitro Antiviral Screening Program
$1,935,624Michael Murray · Southern Research Institute · N01 · FY2010 · AI
Structural Biology of Influenza Epitopes
$1,934,462Audray Harris · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Aging and Immunity to Infections
$1,934,107Susan L Swain · Trudeau Institute, Inc. · P01 · FY2007 · AG
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses
$1,933,284Janet A Englund · Seattle Children'S Hospital · U01 · FY2022 · IP
Host-pathogen competition in IFN mediated antiviral defense
$1,932,378Jae U Jung · University Of Southern California · U19 · FY2011 · AI
Influenza vaccination using a microneedle patch
$1,928,072Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2014 · EB
Emerging Infections Program
$1,927,948Allen S. Craig · Tennessee State Department Of Health · U01 · FY2007 · CI
Emerging respiratory viruses - pathogenesis and countermeasures
$1,927,539Emmie De Wit · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Disordered Proteostasis as a Driver of Disease in the Aging Lung
$1,927,233Gr Scott Budinger · Northwestern University At Chicago · P01 · FY2023 · AG
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$1,924,593Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
IP21-002, New Vaccine Surveillance Network
$1,924,241John V Williams · University Of Pittsburgh At Pittsburgh · U01 · FY2022 · IP
Sample Collection and General Screening Protocols
$1,923,376Lesia Dropulic · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)
$1,919,182Walter A. Orenstein · Emory University · N01 · FY2018 · AI